<p>Lyell Immunopharma（纳斯达克股票代码：LYEL - 获取免费报告）在周四发布的研究报告中被罗伯特·W·贝尔德的投资分析师上调至 “强力买入” 评级，Zacks.com 报道。</p>
<p>LYEL 曾受到多份其他研究报告的关注。华尔街禅在周六的研究报告中将 Lyell Immunopharma 的股票评级从 “持有” 下调至 “卖出”。Zacks Research 在 4 月 7 日的研究报告中将 Lyell Immunopharma 的股票评级从 “持有” 下调至 “强烈卖出”。Citizens Jmp 在 3 月 9 日的研究报告中开始覆盖 Lyell Immunopharma 的股票，给予 “市场表现优于大盘” 评级，并设定 34.00 美元的目标价。Weiss Ratings 在 4 月 21 日的研究报告中重申了对 Lyell Immunopharma 股票的 “卖出（d-）” 评级。最后，Needham &amp; Company LLC 在 4 月 10 日的研究报告中开始覆盖 Lyell Immunopharma 的股票，给予 “买入” 评级，并设定 44.00 美元的目标价。一位研究分析师给予该股票 “强力买入” 评级，三位给予 “买入” 评级，两位给予 “卖出” 评级。根据 MarketBeat.com 的数据，该公司的共识评级为 “适度买入”，共识目标价为 43.00 美元。</p>
<p>获取 <strong>Lyell Immunopharma</strong> 警报：</p>
<p><strong>查看我们对 Lyell Immunopharma 的最新股票分析</strong></p>
<h2>Lyell Immunopharma 股票上涨 5.6%</h2>
<p>纳斯达克：LYEL 周四开盘价为 20.83 美元。Lyell Immunopharma 的 12 个月低点为 7.65 美元，12 个月高点为 45.00 美元。该公司的市值为 4.8596 亿美元，市盈率为-1.28，贝塔值为-0.05。该公司的 50 日移动平均价格为 22.30 美元，200 日移动平均价格为 23.35 美元。</p>
<p>Lyell Immunopharma（纳斯达克股票代码：LYEL - 获取免费报告）最后一次公布财报是在 3 月 12 日，报告显示该季度每股收益（EPS）为（7.68 美元），低于分析师共识预期的（2.15 美元）5.53 美元。Lyell Immunopharma 的股本回报率为-90.52%，净利润率为-762,355.56%。该季度的收入为 0.01 百万美元，而分析师预期为 0.02 百万美元。研究分析师平均预计 Lyell Immunopharma 在当前年度将发布-10.45 的每股收益。</p>
<h2>内部买卖</h2>
<p>在其他新闻中，首席运营官 Stephen J. Hill 在 2 月 11 日的交易中出售了 1,236 股 Lyell Immunopharma 的股票。股票以平均价格 23.39 美元出售，总价值为 28,910.04 美元。出售完成后，首席运营官持有该公司 17,795 股股票，价值 416,225.05 美元。此次交易使其持股减少了 6.49%。该交易在与 SEC 的法律文件中披露，文件可通过此链接获取。此外，首席执行官 Lynn Seely 在 2 月 11 日的交易中出售了 7,455 股 Lyell Immunopharma 的股票。股票以平均价格 23.39 美元出售，总交易额为 174,372.45 美元。出售完成后，首席执行官持有 74,266 股该公司的股票，价值 1,737,081.74 美元。这代表其持股减少了 9.12%。该出售的 SEC 文件提供了更多信息。在过去的九十天里，内部人士共出售了 11,310 股公司股票，价值 264,285 美元。公司内部人士持有公司股票的 22.30%。</p>
<h2>Lyell Immunopharma 的机构交易</h2>
<p>最近，一些对冲基金和其他机构投资者买卖了 LYEL 的股票。GSK plc 在第四季度购买了 Lyell Immunopharma 的新股份，金额为 46,560,000 美元。MWG Caph Ltd 在第四季度购买了 Lyell Immunopharma 的新头寸，金额约为 31,030,000 美元。ARCH Venture Management LLC 在第三季度增加了对 Lyell Immunopharma 的持股，增幅为 51.5%。ARCH Venture Management LLC 现在拥有 2,759,072 股该公司的股票，价值 44,807,000 美元，在上个季度又购买了 938,438 股。Acadian Asset Management LLC 在第一季度增加了对 Lyell Immunopharma 的持股，增幅为 204.2%。Acadian Asset Management LLC 现在拥有 660,899 股该公司的股票，价值 354,000 美元，在上个季度又购买了 443,614 股。最后，Vanguard Group Inc.在第三季度增加了对 Lyell Immunopharma 的持股，增幅为 76.0%。Vanguard Group Inc.现在拥有 779,004 股该公司的股票，价值 12,651,000 美元，在上个季度又购买了 336,378 股。机构投资者持有公司 66.05% 的股票。</p>
<h2>关于 Lyell Immunopharma</h2>
<p>（获取免费报告）</p>
<p>Lyell Immunopharma 是一家临床阶段的生物技术公司，专注于开发针对癌症的下一代 T 细胞疗法。利用一个结合了细胞疗法、基因编辑和分子发现的专有平台，Lyell 旨在克服治疗实体肿瘤的关键障碍。该公司的方法集中在工程化 T 细胞，以增强其持久性、功能性和对免疫抑制肿瘤微环境的抵抗力。</p>
<p>该公司的产品线包括多个自体 T 细胞项目，旨在针对黑色素瘤、卵巢癌和胰腺癌等实体恶性肿瘤中的肿瘤相关抗原。</p>
<h2>推荐故事</h2>
<ul>
<li>我们更看好的五只股票，而不是 Lyell Immunopharma</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TFlFTA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TFlFTA"/></p>
<p><em>此即时新闻警报由叙述科学技术和来自 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 Lyell Immunopharma 吗？</h2>
<p>在考虑 Lyell Immunopharma 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已经识别出五只顶级分析师正在悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 Lyell Immunopharma 并不在名单上。</p>
<p>虽然 Lyell Immunopharma 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

LYEL

<p>罗伯特·W·贝尔德将 Lyell Immunopharma（NASDAQ:LYEL）的评级上调至 “强烈买入”。该公司在分析师中获得了混合评级，包括一项强烈买入、三项买入和两项卖出。目前，其共识评级为 “适度买入”，目标价为 43.00 美元。该股票开盘价为 20.83 美元，上涨 5.6%，市值为 4.8596 亿美元。最近的财报显示每股亏损（7.68 美元），未能达到预期。内部人士最近出售了股票，机构投资者持有该股票的 66.05%</p>

<p>Lyell Immunopharma (NASDAQ:LYEL - Get Free Report) was upgraded by investment analysts at Robert W. Baird to a &#34;strong-buy&#34; rating in a research note issued on Thursday,Zacks.com reports.</p>
<div class="lb-trans"><p>Lyell Immunopharma（纳斯达克股票代码：LYEL - 获取免费报告）在周四发布的研究报告中被罗伯特·W·贝尔德的投资分析师上调至 “强力买入” 评级，Zacks.com 报道。</p>
</div><p>LYEL has been the subject of a number of other research reports. Wall Street Zen cut shares of Lyell Immunopharma from a &#34;hold&#34; rating to a &#34;sell&#34; rating in a research note on Saturday. Zacks Research cut shares of Lyell Immunopharma from a &#34;hold&#34; rating to a &#34;strong sell&#34; rating in a research note on Tuesday, April 7th. Citizens Jmp initiated coverage on shares of Lyell Immunopharma in a research note on Monday, March 9th. They issued a &#34;market outperform&#34; rating and a $34.00 price target for the company. Weiss Ratings reiterated a &#34;sell (d-)&#34; rating on shares of Lyell Immunopharma in a research note on Tuesday, April 21st. Finally, Needham &amp; Company LLC began coverage on shares of Lyell Immunopharma in a research note on Friday, April 10th. They set a &#34;buy&#34; rating and a $44.00 target price for the company. One research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and two have assigned a Sell rating to the company. According to MarketBeat.com, the company has a consensus rating of &#34;Moderate Buy&#34; and a consensus price target of $43.00.</p>
<div class="lb-trans"><p>LYEL 曾受到多份其他研究报告的关注。华尔街禅在周六的研究报告中将 Lyell Immunopharma 的股票评级从 “持有” 下调至 “卖出”。Zacks Research 在 4 月 7 日的研究报告中将 Lyell Immunopharma 的股票评级从 “持有” 下调至 “强烈卖出”。Citizens Jmp 在 3 月 9 日的研究报告中开始覆盖 Lyell Immunopharma 的股票，给予 “市场表现优于大盘” 评级，并设定 34.00 美元的目标价。Weiss Ratings 在 4 月 21 日的研究报告中重申了对 Lyell Immunopharma 股票的 “卖出（d-）” 评级。最后，Needham &amp; Company LLC 在 4 月 10 日的研究报告中开始覆盖 Lyell Immunopharma 的股票，给予 “买入” 评级，并设定 44.00 美元的目标价。一位研究分析师给予该股票 “强力买入” 评级，三位给予 “买入” 评级，两位给予 “卖出” 评级。根据 MarketBeat.com 的数据，该公司的共识评级为 “适度买入”，共识目标价为 43.00 美元。</p>
</div><p>Get <strong>Lyell Immunopharma</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Lyell Immunopharma</strong> 警报：</p>
</div><p><strong>Check Out Our Latest Stock Analysis on Lyell Immunopharma</strong></p>
<div class="lb-trans"><p><strong>查看我们对 Lyell Immunopharma 的最新股票分析</strong></p>
</div><h2>Lyell Immunopharma Stock Up 5.6%</h2>
<div class="lb-trans"><h2>Lyell Immunopharma 股票上涨 5.6%</h2>
</div><p>NASDAQ:LYEL opened at $20.83 on Thursday. Lyell Immunopharma has a 12-month low of $7.65 and a 12-month high of $45.00. The firm has a market capitalization of $485.96 million, a PE ratio of -1.28 and a beta of -0.05. The firm has a 50-day moving average price of $22.30 and a 200 day moving average price of $23.35.</p>
<div class="lb-trans"><p>纳斯达克：LYEL 周四开盘价为 20.83 美元。Lyell Immunopharma 的 12 个月低点为 7.65 美元，12 个月高点为 45.00 美元。该公司的市值为 4.8596 亿美元，市盈率为-1.28，贝塔值为-0.05。该公司的 50 日移动平均价格为 22.30 美元，200 日移动平均价格为 23.35 美元。</p>
</div><p>Lyell Immunopharma (NASDAQ:LYEL - Get Free Report) last announced its earnings results on Thursday, March 12th. The company reported ($7.68) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($2.15) by ($5.53). Lyell Immunopharma had a negative return on equity of 90.52% and a negative net margin of 762,355.56%.The company had revenue of $0.01 million for the quarter, compared to analyst estimates of $0.02 million. On average, research analysts expect that Lyell Immunopharma will post -10.45 EPS for the current year.</p>
<div class="lb-trans"><p>Lyell Immunopharma（纳斯达克股票代码：LYEL - 获取免费报告）最后一次公布财报是在 3 月 12 日，报告显示该季度每股收益（EPS）为（7.68 美元），低于分析师共识预期的（2.15 美元）5.53 美元。Lyell Immunopharma 的股本回报率为-90.52%，净利润率为-762,355.56%。该季度的收入为 0.01 百万美元，而分析师预期为 0.02 百万美元。研究分析师平均预计 Lyell Immunopharma 在当前年度将发布-10.45 的每股收益。</p>
</div><h2>Insider Buying and Selling</h2>
<div class="lb-trans"><h2>内部买卖</h2>
</div><p>In other news, COO Stephen J. Hill sold 1,236 shares of Lyell Immunopharma stock in a transaction on Wednesday, February 11th. The shares were sold at an average price of $23.39, for a total value of $28,910.04. Following the completion of the sale, the chief operating officer owned 17,795 shares in the company, valued at $416,225.05. The trade was a 6.49% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO Lynn Seely sold 7,455 shares of Lyell Immunopharma stock in a transaction on Wednesday, February 11th. The shares were sold at an average price of $23.39, for a total transaction of $174,372.45. Following the completion of the sale, the chief executive officer owned 74,266 shares of the company's stock, valued at $1,737,081.74. This represents a 9.12% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 11,310 shares of company stock worth $264,285 in the last ninety days. Company insiders own 22.30% of the company's stock.</p>
<div class="lb-trans"><p>在其他新闻中，首席运营官 Stephen J. Hill 在 2 月 11 日的交易中出售了 1,236 股 Lyell Immunopharma 的股票。股票以平均价格 23.39 美元出售，总价值为 28,910.04 美元。出售完成后，首席运营官持有该公司 17,795 股股票，价值 416,225.05 美元。此次交易使其持股减少了 6.49%。该交易在与 SEC 的法律文件中披露，文件可通过此链接获取。此外，首席执行官 Lynn Seely 在 2 月 11 日的交易中出售了 7,455 股 Lyell Immunopharma 的股票。股票以平均价格 23.39 美元出售，总交易额为 174,372.45 美元。出售完成后，首席执行官持有 74,266 股该公司的股票，价值 1,737,081.74 美元。这代表其持股减少了 9.12%。该出售的 SEC 文件提供了更多信息。在过去的九十天里，内部人士共出售了 11,310 股公司股票，价值 264,285 美元。公司内部人士持有公司股票的 22.30%。</p>
</div><h2>Institutional Trading of Lyell Immunopharma</h2>
<div class="lb-trans"><h2>Lyell Immunopharma 的机构交易</h2>
</div><p>A number of hedge funds and other institutional investors have recently bought and sold shares of LYEL. GSK plc bought a new stake in shares of Lyell Immunopharma in the 4th quarter worth $46,560,000. MWG Caph Ltd purchased a new position in shares of Lyell Immunopharma in the 4th quarter worth about $31,030,000. ARCH Venture Management LLC boosted its holdings in shares of Lyell Immunopharma by 51.5% in the 3rd quarter. ARCH Venture Management LLC now owns 2,759,072 shares of the company's stock worth $44,807,000 after buying an additional 938,438 shares during the last quarter. Acadian Asset Management LLC boosted its holdings in shares of Lyell Immunopharma by 204.2% in the 1st quarter. Acadian Asset Management LLC now owns 660,899 shares of the company's stock worth $354,000 after buying an additional 443,614 shares during the last quarter. Finally, Vanguard Group Inc. boosted its holdings in shares of Lyell Immunopharma by 76.0% in the 3rd quarter. Vanguard Group Inc. now owns 779,004 shares of the company's stock worth $12,651,000 after buying an additional 336,378 shares during the last quarter. Institutional investors own 66.05% of the company's stock.</p>
<div class="lb-trans"><p>最近，一些对冲基金和其他机构投资者买卖了 LYEL 的股票。GSK plc 在第四季度购买了 Lyell Immunopharma 的新股份，金额为 46,560,000 美元。MWG Caph Ltd 在第四季度购买了 Lyell Immunopharma 的新头寸，金额约为 31,030,000 美元。ARCH Venture Management LLC 在第三季度增加了对 Lyell Immunopharma 的持股，增幅为 51.5%。ARCH Venture Management LLC 现在拥有 2,759,072 股该公司的股票，价值 44,807,000 美元，在上个季度又购买了 938,438 股。Acadian Asset Management LLC 在第一季度增加了对 Lyell Immunopharma 的持股，增幅为 204.2%。Acadian Asset Management LLC 现在拥有 660,899 股该公司的股票，价值 354,000 美元，在上个季度又购买了 443,614 股。最后，Vanguard Group Inc.在第三季度增加了对 Lyell Immunopharma 的持股，增幅为 76.0%。Vanguard Group Inc.现在拥有 779,004 股该公司的股票，价值 12,651,000 美元，在上个季度又购买了 336,378 股。机构投资者持有公司 66.05% 的股票。</p>
</div><h2>About Lyell Immunopharma</h2>
<div class="lb-trans"><h2>关于 Lyell Immunopharma</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Lyell Immunopharma is a clinical-stage biotechnology company focused on developing next-generation T cell therapies for cancer. Leveraging a proprietary platform that combines cell therapy, gene editing and molecular discovery, Lyell seeks to overcome key barriers in the treatment of solid tumors. The company's approach centers on engineering T cells to enhance their persistence, functionality and resistance to the immunosuppressive tumor microenvironment.</p>
<div class="lb-trans"><p>Lyell Immunopharma 是一家临床阶段的生物技术公司，专注于开发针对癌症的下一代 T 细胞疗法。利用一个结合了细胞疗法、基因编辑和分子发现的专有平台，Lyell 旨在克服治疗实体肿瘤的关键障碍。该公司的方法集中在工程化 T 细胞，以增强其持久性、功能性和对免疫抑制肿瘤微环境的抵抗力。</p>
</div><p>The company's pipeline includes multiple autologous T cell programs engineered to target tumor-associated antigens in solid malignancies such as melanoma, ovarian and pancreatic cancers.</p>
<div class="lb-trans"><p>该公司的产品线包括多个自体 T 细胞项目，旨在针对黑色素瘤、卵巢癌和胰腺癌等实体恶性肿瘤中的肿瘤相关抗原。</p>
</div><h2>Recommended Stories</h2>
<div class="lb-trans"><h2>推荐故事</h2>
</div><ul>
<li>Five stocks we like better than Lyell Immunopharma</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票，而不是 Lyell Immunopharma</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TFlFTA" alt="" original-src="https://www.marketbeat.com/scripts/RatingsChart.ashx?Prefix=NASDAQ&amp;Symbol=LYEL"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻警报由叙述科学技术和来自 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Lyell Immunopharma Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Lyell Immunopharma 吗？</h2>
</div><p>Before you consider Lyell Immunopharma, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Lyell Immunopharma 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Lyell Immunopharma wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已经识别出五只顶级分析师正在悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 Lyell Immunopharma 并不在名单上。</p>
</div><p>While Lyell Immunopharma currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Lyell Immunopharma 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Lyell Immunopharma (NASDAQ:LYEL) Upgraded by Robert W. Baird to Strong-Buy Rating

Market Beat

Lyell Immunopharma（纳斯达克股票代码：LYEL）被 Robert W. Baird 上调至强力买入评级